期刊文献+

计算机辅助设计HER2/neu酪氨酸激酶小分子抑制剂及其生物活性研究 被引量:8

Discovery of HER2/neu Tyrosine Kinase Inhibitor through Computer- Aided Drug Design Approach and its Biological Activity
下载PDF
导出
摘要 目的:用计算机辅助设计法寻找 HER2/neu受体酪氨酸激酶小分子抑制剂。方法:用 MODERLAR软件模拟出 HER2/neu和 EGFR受体酪氨酸激酶的三维 (three- dimensional,3D)空间结构;根据 HER2/neu酪氨酸激酶 ATP结合区的空间结构,搜索数据库,找出候选化合物;用 Western blot方法检测化合物对 HER2/neu受体酪氨酸激酶磷酸化的影响; MTT法检测细胞增殖抑制作用。结果:比较 HER2/neu和 EGFR(靶蛋白)与胰岛素受体酪氨酸激酶、 FGFR1受体酪氨酸激酶和 Src酪氨酸激酶(模板蛋白)的氨基酸序列发现有 35%~ 41%的相同和 52%~ 55%的相似,用 MODELLER程序模拟出 HER2/neu和 EGFR激酶区域的 3D结构。根据 HER2/neu受体酪氨酸激酶结构模型, 3D数据库的搜索,获得潜在 HER2/neu酪氨酸激酶抑制剂化合物,经筛选、优化发现 ST2325对 HER2/neu磷酸化有明显的抑制作用,其 IC50值为 6.6μ mol/L,且抑制作用是可逆的,对 EGFR受体磷酸化没有抑制作用。 ST2325对 HER2/neu受体表达没有影响。 ST2325对 HER2/neu过表达的肿瘤细胞 MDA- MB- 453 m1的抑制作用更强,而对 EGFR过表达的肿瘤细胞 MDA- MB- 468抑制作用相对较弱,其 IC50值分别为 29.05μ mol/L和 60.40μ mol/L。结论:基于 HER2/neu的结构设计,筛选? Objective: To discover HER2/neu tyrosine kinase inhibitor through computer- aided drug design approach. Methods: The three- dimensional(3D) structure of HER2/neu and EGFR tyrosine kinase domain was modeled using MODERLAR software. To search database and pick up candidate compounds based 3D structure of HER2/neu tyrosine kinase domain. Inhibition of HER2/neu tyrosine kinase phosphorylation by the compounds was detected using Western blot analysis. Inhibition of cell proliferation was determined by MTT assay. Results: The amino acid identity and similarity between HER2/neu and EGFR kinase domain, insulin receptor kinase domain, FGFR1 kinase domain, Src kinase domain were compared. The identity was 35%- 41% and the similarity was 52%- 55% . The 3D structure of HER2/neu and EGFR was obtained by MODERLAR software. Through searching, screening and optimization, the authors found that ST2325 had significantly inhibitory effect on HER2/neu tyrosine kinase phosphorylation with IC50 of 6.6μ mol/L. The inhibition of HER2/neu phosphorylation was selective and reversible. ST2325 inhibited cell proliferation of HER2/neu- overexpressing MDA- MB- 453m1 preferentially compared with EGFR- overexpressing MDA- MB- 468, The IC50 values were 29.05 and 60.4μ mol/L. Conclusion: ST2325 which was discovered through structure- based approach had notable inhibitory effect on HER2/neu tyrosine kinase.
出处 《癌症》 SCIE CAS CSCD 北大核心 2001年第4期341-347,共7页 Chinese Journal of Cancer
基金 国家自然科学基金资助项目!(编号:39900183)
关键词 HER2/NEU 酪氨酸激酶抑制剂 计算机辅助设计 抗癌药物 : HER2/neu Tyrosine kinase inhibitor Computer- aided drug design Anticancer drug
  • 相关文献

参考文献5

  • 1Ross J S,Am J Clin Pathol,1999年,111卷,3期,311页
  • 2Fong T A,Cancer Res,1999年,59卷,1期,99页
  • 3Liu M,J Comput Aided Mol Des,1999年,13卷,5期,435页
  • 4Huang M C,Seminars Oncology,1999年,26卷,4 suppl期,51页
  • 5Mohammadi M,Science,1997年,276卷,5314期,955页

同被引文献48

  • 1蒋毅,郭宗儒.表皮生长因子受体的ATP竞争性抑制剂[J].有机化学,2004,24(12):1640-1643. 被引量:3
  • 2丁乂,俞莉章,李鸣,刘漓波,钟华.人肾颗粒细胞癌细胞系(GRC-1)的建立及其生物学特性[J].中华泌尿外科杂志,1995,16(1):3-6. 被引量:17
  • 3Abou-Jawde R, Choueiri T, Alemany C, et al. An overview of targeted treatments in cancer[J]. Clin Ther, 2003,25(8) :2121.
  • 4Mass RD. The HER receptor family:a rich target for therapeutic development[J]. Int J Radiat Oncol Biol Phys ,2004,58(3) :932.
  • 5Lewis LD, Beelen AP, Cole BF, et al. The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma1b in a multiple-dose phase I study in patients with advanced cancer [J]. Cancer Chemother Pharacol,2002,49(5) :375.
  • 6van Ojik HH, Repp R, Groenewegen G, et al. Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcgRI' anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor(Filgrastim) for treatment of advanced breast cancer[ J]. Cancer Immunol Immunother,1997,45(3-4) :207.
  • 7ZhouH, KimYS, PeletierA, etal. Effects of the EGFR/HER2 Kinase inhibitor GW572016 on EGFR and HER2-overexpressing breast cancer cell line proliferation, radiosensitization and resistance[J]. Int J Radiat Oncol Biol Phys ,2004,58(2) :344.
  • 8Burris HA Ⅲ. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/Erb B-2 inhibitor lapatinib[ J ].Oncologist ,2004, (Suppl 3): 10.
  • 9Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors [ J ]. Lung Cancer, 2003,41 (Suppl 1 ): S43.
  • 10Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy[J]. EMBO J,2002,21 (10) :2407.

引证文献8

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部